Loading...
•
Jun 30, 2020
Corcept Therapeutics Q2 2020 Earnings Report
Reported a 23 percent revenue increase and reaffirmed 2020 revenue guidance.
Key Takeaways
Corcept Therapeutics reported a revenue of $88.6 million for the second quarter of 2020, a 23% increase compared to the same period in 2019. The company's GAAP diluted net income per share was $0.23, and non-GAAP diluted net income per share was $0.32. They reaffirmed their 2020 revenue guidance of $355 – 375 million.
Revenue of $88.6 million, a 23 percent increase from second quarter 2019
GAAP diluted net income of $0.23 per share, compared to $0.17 per share in second quarter 2019
Non-GAAP diluted net income of $0.32 per share, compared to $0.25 per share in second quarter 2019
Cash and investments of $409.6 million, compared to $349.0 million at March 31, 2020
Forward Guidance
Corcept Therapeutics reaffirms its 2020 revenue guidance of $355 - $375 million, expecting countervailing forces from the pandemic to continue in the coming quarters but remain manageable.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...